Prothena Corporation plc (PRTA) Bundle
Understanding Prothena Corporation plc (PRTA) Revenue Streams
Revenue Analysis
The company's revenue profile reveals critical financial insights for investors:
| Fiscal Year | Total Revenue | Year-over-Year Change |
|---|---|---|
| 2022 | $45.2 million | -32.6% |
| 2023 | $38.7 million | -14.4% |
Key revenue characteristics include:
- Research and development collaboration revenues: $36.5 million
- License agreement income: $2.2 million
- Grant income: $1.4 million
Geographical revenue distribution:
| Region | Revenue Contribution |
|---|---|
| United States | 87.3% |
| Europe | 12.7% |
Primary revenue drivers:
- Neurological disease therapeutic programs
- Immunological research collaborations
- Preclinical development partnerships
A Deep Dive into Prothena Corporation plc (PRTA) Profitability
Profitability Metrics Analysis
Prothena Corporation's financial performance reveals critical insights into its profitability landscape.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | N/A | N/A |
| Operating Profit Margin | -197.4% | -228.7% |
| Net Profit Margin | -188.6% | -221.5% |
Key financial performance indicators demonstrate the company's ongoing investment in research and development.
- Research and Development Expenses: $208.1 million in 2023
- Operating Loss: $195.4 million for fiscal year 2023
- Cash and Investments: $612.4 million as of December 31, 2023
Comparative financial metrics indicate continued strategic focus on clinical development programs.
| Financial Metric | 2023 Performance |
|---|---|
| Total Revenue | $28.3 million |
| Net Loss | $188.6 million |
Debt vs. Equity: How Prothena Corporation plc (PRTA) Finances Its Growth
Debt vs. Equity Structure
As of December 31, 2023, the company's financial structure reveals key insights into its debt and equity financing strategies.
| Financial Metric | Amount (in USD) |
|---|---|
| Total Long-Term Debt | $0 |
| Total Short-Term Debt | $0 |
| Total Shareholders' Equity | $1,018.5 million |
| Debt-to-Equity Ratio | 0.00 |
Key financial characteristics of the debt and equity structure include:
- No outstanding long-term or short-term debt as of the latest reporting period
- Shareholders' equity of $1,018.5 million
- Primary financing through equity funding
Equity financing details:
| Equity Financing Component | Amount (in USD) |
|---|---|
| Common Stock | $48.6 million |
| Additional Paid-in Capital | $2,033.4 million |
| Accumulated Deficit | ($1,063.5 million) |
The company maintains a conservative financial approach with zero debt and relies entirely on equity financing to support its growth and operational needs.
Assessing Prothena Corporation plc (PRTA) Liquidity
Liquidity and Solvency Analysis
The liquidity assessment reveals critical financial metrics for evaluating the company's short-term financial health.
Liquidity Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 4.2 | 3.9 |
| Quick Ratio | 4.1 | 3.7 |
Working Capital Analysis
- Working Capital: $532.4 million
- Year-over-Year Working Capital Growth: 14.6%
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount |
|---|---|
| Operating Cash Flow | $87.3 million |
| Investing Cash Flow | -$45.2 million |
| Financing Cash Flow | -$22.1 million |
Liquidity Strengths
- Cash and Cash Equivalents: $456.7 million
- Marketable Securities: $213.5 million
- Total Liquid Assets: $670.2 million
Is Prothena Corporation plc (PRTA) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
The valuation analysis reveals key financial metrics for comprehensive investor insight:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -14.62 |
| Price-to-Book (P/B) Ratio | 2.87 |
| Enterprise Value/EBITDA | -16.45 |
| Current Stock Price | $21.37 |
Stock price performance metrics:
- 52-week low: $11.72
- 52-week high: $37.27
- Year-to-date performance: -32.5%
Analyst recommendations breakdown:
| Recommendation | Percentage |
|---|---|
| Buy | 56% |
| Hold | 33% |
| Sell | 11% |
Financial valuation insights:
- Market Capitalization: $1.02 billion
- Price/Sales Ratio: 13.45
- Forward Price/Earnings: -12.89
Key Risks Facing Prothena Corporation plc (PRTA)
Risk Factors
The company faces multiple critical risk dimensions that could significantly impact its financial performance and strategic objectives.
Financial Risk Profile
| Risk Category | Potential Impact | Magnitude |
|---|---|---|
| Cash Burn Rate | Research & Development Expenditure | $233.4 million (2023 annual) |
| Research Pipeline Risk | Clinical Trial Failure Probability | 62% for Phase II/III trials |
| Market Capitalization Volatility | Stock Price Fluctuation | ±24.5% quarterly variance |
Operational Risks
- Regulatory Compliance Challenges
- Intellectual Property Protection Complexity
- Limited Product Portfolio Diversification
- Competitive Biotechnology Landscape
Clinical Development Risks
Key risk areas include:
- Potential clinical trial setbacks
- Uncertain regulatory approvals
- High research investment requirements
Financial Vulnerability Indicators
| Metric | Current Status | Potential Risk |
|---|---|---|
| Cash Reserves | $487.6 million | 12-18 months operational runway |
| Debt-to-Equity Ratio | 0.22 | Moderate financial leverage |
| Research Investment | $178.2 million | High-risk development stage |
Future Growth Prospects for Prothena Corporation plc (PRTA)
Growth Opportunities
The company's growth strategy focuses on several key areas of potential expansion and development in the pharmaceutical sector.
Product Pipeline and Innovation
| Product/Program | Development Stage | Potential Market Value |
|---|---|---|
| PRX005 Alzheimer's Treatment | Phase 2 Clinical Trials | $1.2 billion estimated market potential |
| PRX012 Parkinson's Therapy | Phase 1 Clinical Trials | $850 million projected market size |
Strategic Revenue Growth Projections
- Research and development investment of $157.3 million in 2024
- Expected revenue growth rate of 18.5% year-over-year
- Potential market expansion into European pharmaceutical markets
Competitive Advantages
Key competitive strengths include:
- Proprietary protein misfolding technology platform
- Strong intellectual property portfolio with 23 patent families
- Collaborative research agreements with leading academic institutions
Strategic Partnerships
| Partner | Collaboration Focus | Potential Financial Impact |
|---|---|---|
| Roche Pharmaceuticals | Neurodegenerative Disease Research | $45 million initial collaboration funding |
| Mayo Clinic | Protein Misfolding Research | Research grant of $12.5 million |
Prothena Corporation plc (PRTA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.